Technology area: Biotechnology & Pharmaceuticals
151 pending office actions • 91 clients • 137 examiners • 90 art units • 0 of 151 (0%) have an AI response strategy ready
Lathrop GPM LLP works in Biotechnology & Pharmaceuticals and has 6,812 career applications. The profile records 154 pending office actions and a resolved allowance rate of 83.14%. Allowance is the recorded result for most resolved matters, while the rate also shows that a portion resolved without allowance.
The average of 3.49 office actions per allowance describes activity associated with allowed matters. This is distinct from the allowance rate because it measures prosecution effort rather than outcome. The pending docket identifies a substantial current workload, and the application history provides scale for practitioners reviewing resolution patterns, case attention, and office-action activity.
Based on the USPTO statutory response window for each pending office action. 35 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 35 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 3 (2%) |
| §101 + other | 22 (15%) |
| §103 only | 33 (22%) |
| §102 only | 12 (8%) |
| §112 only | 5 (3%) |
| Double-patenting only | 3 (2%) |
| Double-patenting + other | 19 (13%) |
| Multi-statute (no §101) | 53 (35%) |
| No statute on record | 1 (1%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMANI, NILOOFAR | 5 | 77.6% | -2.9% |
| GUSTILO, ESTELLA M | 3 | 53.6% | +34.5% |
| VANHORN, ABIGAIL LOUISE | 2 | 46.8% | +22.7% |
| POLIAKOVA-GEORGAN, EKATERINA | 2 | 63.9% | +18.1% |
| WARD, AARON DUREL | 2 | 0.0% | +0.0% |
| ZARA, JANE J | 2 | 71.0% | +16.1% |
| MUI, CHRISTINE T | 2 | 78.4% | +19.8% |
| SCHLIENTZ, LEAH H | 2 | 41.8% | +38.7% |
| CRAIG, KAILA ANGELIQUE | 2 | 33.8% | +25.2% |
| HOPPE, EMMA RUTH | 2 | 40.0% | +58.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17262400 | METHOD FOR PRODUCING FOREIGN ANTIGEN RECEPTOR GENE-INTRODUCED CELL | MIANO, JOSEPH PAUL | 87d overdue |
| 18039091 | NON AGGREGATING MICROFLUIDIC MIXER AND METHODS THEREFOR | INSLER, ELIZABETH | 11d overdue |
| 18049724 | COMPLEXES FOR GENE DELETION AND EDITING | LEONARD, ARTHUR S | 11d overdue |
| 18439838 | FUNTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | STEELE, AMBER D | 9d overdue |
| 18684682 | COMPOSITION COMPRISING PASTEURIZED AKKERMANSIA FOR THE TREATMENT OR PREVENTION OF IBS-RELATED ANXIETY | MOREAU, NASHARA LOUISE | 8d overdue |
| 18120030 | OLIGONUCLEOTIDES FOR APP MODULATION | ALLEN, SARAH ELIZABETH | 2d overdue |
| 18252896 | METHOD FOR DETECTING AND/OR QUANTIFYING A METAL ELEMENT IN A BIOLOGICAL LIQUID | GAMBLE JR, RANDALL LEE | 14d |
| 18271112 | MEDIUM FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, METHOD FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, AND METHOD FOR PRODUCING RENAL ORGANOIDS | O'NEILL, MARISOL ANN | 21d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16998587 | TARGETED FLUORESCENT MARKERS IN COMBINATION WITH A FLEXIBLE PROBE | SCHLIENTZ, LEAH H | 162d overdue |
| 18299304 | THERAPEUTIC RADIOLABELLED CONJUGATES AND THEIR USE IN THERAPY | CRAIG, KAILA ANGELIQUE | 23d overdue |
| 18269668 | CLINICAL LABORATORY AUTOMATION SYSTEM WITH SINGLE CALIBRATOR | MUI, CHRISTINE T | 53d |
| 19568680 | YEAST CELL WALL PARTICLE ENCAPSULATION OF BIODEGRADABLE PRO-PAYLOADS | VANHORN, ABIGAIL LOUISE | — |
| 18705038 | USE OF A MODIFIED B-CAROTENE KETOLASE (BKT) OR A CORRESPONDING NUCLEIC ACID FOR IMPROVING RESISTANCE TO OXIDATIVE STRESS AND/OR PHOTOINHIBITION OF HOST ORGANISMS, IMPROVING BIOMASS PRODUCTIVITY OF HOST ORGANISMS AND/OR PREVAILING OVER OTHER COMPETING ORGANISMS UPON CULTIVATION IN HIGH LIGHT CONDITIONS | POLIAKOVA-GEORGAN, EKATERINA | — |
| 18639584 | METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | GUSTILO, ESTELLA M | — |
| 18696689 | MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION THERAPY | GUSTILO, ESTELLA M | — |
| 18396613 | BRANCHED OLIGONUCLEOTIDES | ZARA, JANE J | — |
| Art Unit | Apps |
|---|---|
| 1636 | 7 |
| 1618 | 7 |
| 1691 | 5 |
| 1637 | 5 |
| 3685 | 4 |
| 2881 | 4 |
| 1693 | 4 |
| 1654 | 4 |
| 1635 | 4 |
| 1622 | 3 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19568680 | YEAST CELL WALL PARTICLE ENCAPSULATION OF BIODEGRADABLE PRO-PAYLOADS | UNIVERSITY OF MASSACHUSETTS | VANHORN, ABIGAIL LOUISE | 1636 | §103§112DP | Non-Final OA | — | Pending | Mar 16, 2026 |
| 19395349 | USE OF PASTEURIZED AKKERMANSIA FOR TREATING METABOLIC DISORDERS | Compagnie Gervais Danone | NGUYEN, NGHI V | 1653 | §102Other | Final Rejection | — | Pending | Nov 20, 2025 |
| 19378987 | PORTABLE CONTAINER WITH SIMULTANEOUS COLLAPSIBLE SUPPORT FEET | Packfire, Inc. | CASTELLANO, STEPHEN J | 3733 | §102§103§112 | Final Rejection | — | Pending | Nov 04, 2025 |
| 19354420 | METHODS AND SYSTEMS TO INDUCE REFLECTION BASED ON EMOTIONAL VALENCE | Sequelae, Inc. | O'SHEA, BRENDAN S | 3626 | §101§102§103 | Non-Final OA | — | Pending | Oct 09, 2025 |
| 19325002 | SYSTEM AND DEVICE FOR MAXILLOMANDIBULAR FIXATION | Invisian Medical, LLC | RUIZ MARTIN, LUIS MIGUEL | 3772 | §103 | Final Rejection | — | Pending | Sep 10, 2025 |
| 19321862 | METHODS AND SYSTEMS FOR IMPROVING AN EFFECTIVENESS OF REFLECTION BY AN INDIVIDUAL MEMBER | Sequelae, Inc. | COBANOGLU, DILEK B | 3687 | §101§102§112 | Non-Final OA | — | Pending | Sep 08, 2025 |
| 19322416 | SYSTEMS AND METHODS FOR SCORING LANGUAGE MODEL OUTPUTS USING A SCORING MODEL | Cable Television Laboratories, Inc. | CAIADO, ANTONIO J | 2164 | §101§102§103 | Non-Final OA | — | Pending | Sep 08, 2025 |
| 19301806 | TRAJECTORY VALUE LEARNING FOR AUTONOMOUS SYSTEMS | Waabi Innovation Inc. | NGUYEN, TAN QUANG | 3661 | DP | Non-Final OA | — | Pending | Aug 15, 2025 |
| 19287736 | ADAPTIVE AUTO-DRILLING FOR DRILLING APPLICATIONS | Flanders Electric Motor Service, LLC | WLODARSKI, NICHOLAS NMN | 3672 | §101 | Final Rejection | — | Pending | Jul 31, 2025 |
| 19271284 | PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDE | Scpharmaceuticals Inc. | HUANG, GIGI GEORGIANA | 1613 | §103DP | Non-Final OA | 7d | Pending | Jul 16, 2025 |
| 19269487 | ANTIBODY-DRUG CONJUGATES USING TWO DIFFERENT TYPES OF TOPOISOMERASE I INHIBITORS | Araris Biotech AG | VISHNYAKOVA, ELENA VLADIMIROVNA | 1691 | §103§112DP | Non-Final OA | — | Pending | Jul 15, 2025 |
| 19137361 | MEASUREMENT DEVICE AND DRILL GUIDE | Arthrex, Inc. | SIPP, AMY R. | 3775 | §102§103§112 | Final Rejection | — | Pending | Jun 10, 2025 |
| 19224021 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS | Wageningen Universiteit | GOUGH, TIFFANY MAUREEN | 1651 | §101DP | Final Rejection | — | Pending | May 30, 2025 |
| 19222001 | SYSTEMS AND METHODS FOR QUANTIFYING NETWORK QUALITY USING A SCORING MODEL | Cable Television Laboratories, Inc. | HUSSAIN, TAUQIR | 2449 | §101§103 | Non-Final OA | — | Pending | May 29, 2025 |
| 19210707 | SYSTEMS AND METHODS FOR AUTOMATICALLY GENERATING A RECORD IN A DIGITAL COMMUNICATION NETWORK | Sequelae, Inc. | LAGOY, KYRA RAND | 3685 | §101§103 | Final Rejection | — | Pending | May 16, 2025 |
| 19120654 | ANTIFIBROTIC AGENT, PHARMACEUTICAL COMPOSITION FOR TREATING FIBROSIS, AND METHOD FOR INACTIVATING MYOFIBROBLASTS | Somar Corporation | LI, WENHAN | 1614 | §103§112DP | Non-Final OA | — | Pending | Apr 11, 2025 |
| 19174814 | ARTIFICIAL INTELLIGENCE POWERED CHIEF OF STAFF BOT | TransforML Platforms Inc. | FILIPCZYK, MARCIN R | 2153 | §103 | Final Rejection | 23d overdue | Pending | Apr 09, 2025 |
| 19114282 | NEURAL HASH GRID BASED MULTI-SENSOR SIMULATION | Waabi Innovation Inc. | LI, JAI WEI TOMMY | 2613 | §103 | Non-Final OA | — | Pending | Mar 21, 2025 |
| 19083908 | SYSTEMS AND METHODS FOR SUPPORTING HEALTH-BASED COMMUNICATIONS | Sequelae, Inc. | SIOZOPOULOS, CONSTANTINE B | 3686 | §101§102 | Non-Final OA | — | Pending | Mar 19, 2025 |
| 19073684 | SYSTEMS AND METHODS FOR INCENTIVIZING HEALTH-BASED INTERVENTIONS BASED ON INFLUENCE IN A DIGITAL COMMUNICATION NETWORK | Sequelae, Inc. | RASNIC, HUNTER J | 3684 | §101§103 | Final Rejection | — | Pending | Mar 07, 2025 |
| 19072084 | METHODS AND SYSTEMS FOR DETERMINING AN INTERVENTION BASED TREATMENT FOR CHRONIC MEDICAL CONDITIONS | Sequelae, Inc. | GARTLAND, SCOTT D | 3685 | §101 | Final Rejection | — | Pending | Mar 06, 2025 |
| 19065033 | METHODS AND SYSTEMS FOR DETERMINING STRESS RESILIENCY | Sequelae, Inc. | SAINT-VIL, EDDY | 3715 | §101§103 | Non-Final OA | — | Pending | Feb 27, 2025 |
| 18980424 | BICYCLOOCTANE KRAS INHIBITORS | Incyte Corporation | RAHMANI, NILOOFAR | 1691 | §102§112 | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18949302 | ROAD MAPPING FRAMEWORK | Waabi Innovation Inc. | LIN, JESSICA YIFANG | 2668 | §102§103 | Non-Final OA | — | Pending | Nov 15, 2024 |
| 18948416 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | Alkermes Pharma Ireland Limited | WARD, PAUL V | 1622 | §112DP | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18936436 | SYSTEM AND METHOD FOR PLANK PROCESSING | Shaw Industries Group, Inc. | MUDD, HENRY HOOPER | 3642 | §102 | Non-Final OA | — | Pending | Nov 04, 2024 |
| 18925317 | SYSTEMS AND METHODS FOR RECONFIGURABLE COHERENT PON | Cable Television Laboratories, Inc. | PHAN, HANH | 2634 | §103 | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18900771 | SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER | On Target Laboratories, Inc. | DICKINSON, PAUL W | 1618 | §101§112 | Non-Final OA | — | Pending | Sep 29, 2024 |
| 18896259 | N-OXIDE INHIBITORS OF NLRP3 INFLAMMASOME | BIOAGE LABS, INC. | RAHMANI, NILOOFAR | 1691 | §112DP | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18849834 | 3,4,6,7-TETRAHYDRO-2,7-NAPHTHYRIDINE-2(1H)-CARBOXAMIDE DERIVATIVES AS GPR65 INHIBITORS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Pathios Therapeutics Limited | STOCKTON, LAURA LYNNE | 1626 | §102§112 | Non-Final OA | — | Pending | Sep 23, 2024 |
| 18886490 | BALLOON INFLATION SYSTEM AND METHODS | Anagram International, LLC | KASENGE, CHARLES R | 2116 | §102 | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18841615 | SYSTEMS AND METHODS FOR CAPILLARY ISOELECTRIC FOCUSING-MASS SPECTROMETRY (CIEF-MS) ISOELECTRIC POINT (pI) CALIBRATION | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. | WANG, JING | 2881 | §101§103§112 | Non-Final OA | — | Pending | Aug 26, 2024 |
| 18839971 | METHOD FOR CHECK MEASUREMENT OF A LOG PROCESSED WITH TREE-HANDLING DEVICE, CORRESPONDING MEASUREMENT SYSTEM, FOREST MACHINE AND HARDWARE | Ponsse Oyj | QUINN, DANIEL MICHAEL | 2855 | §101§102§103§112 | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18835285 | AUTONOMOUS SYSTEM TRAINING AND TESTING | Waabi Innovation Inc. | TSWEI, YU-JANG | 2614 | §103 | Final Rejection | 9d | Pending | Aug 01, 2024 |
| 18832725 | LIQUID FORMULATION COMPRISING A FUSION PROTEIN INCLUDING a-GALACTOSIDASE A | Hanmi Pharm. Co., Ltd. | CRAIGO, WILLIAM A | 1615 | §103Other | Final Rejection | — | Pending | Jul 24, 2024 |
| 18780957 | HIDDEN EDGE FOR FLOORING FINISHING | Columbia Insurance Company | MAESTRI, PATRICK J | 3635 | §102§103 | Non-Final OA | 28d | Pending | Jul 23, 2024 |
| 18729403 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | Almac Discovery Limited | HEITMEIER, KENDALL NICOLE | 1621 | §103§112DP | Non-Final OA | — | Pending | Jul 16, 2024 |
| 18759774 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. | RAHMANI, NILOOFAR | §103 | Non-Final OA | — | Pending | Jun 28, 2024 | |
| 18724755 | REFRIGERATED PROCESSED FOODS OF EXTENDED DURABILITY AND METHOD FOR THE CONSERVATION THEREOF | Coroos Beheer BV | LEFF, STEVEN N | 1792 | §103§112 | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18722680 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SGLT-2 INHIBITOR AND GOSSYPOL | Haim Bio., Ltd. | GALSTER, SAMUEL LEONARD | 1693 | §103§112 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18717119 | DECORATIVE ARTICLE DELIVERY DEVICE | Shaw Industries Group, Inc. | STABLEY, MICHAEL R | 3611 | §102§103§112 | Non-Final OA | — | Pending | Jun 06, 2024 |
| 18715638 | CAPILLARY ELECTROPHORESIS METHODS FOR CHARACTERIZING GENOME INTEGRITY | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. | CHEN, STACY BROWN | 1672 | §103 | Non-Final OA | — | Pending | May 31, 2024 |
| 18678931 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation | AULAKH, CHARANJIT | 1621 | §112 | Final Rejection | — | Pending | May 30, 2024 |
| 18675743 | PYRAZOLOQUINOLINE KRAS INHIBITORS | Incyte Corporation | RAHMANI, NILOOFAR | 1691 | §102 | Non-Final OA | — | Pending | May 28, 2024 |
| 18705038 | USE OF A MODIFIED B-CAROTENE KETOLASE (BKT) OR A CORRESPONDING NUCLEIC ACID FOR IMPROVING RESISTANCE TO OXIDATIVE STRESS AND/OR PHOTOINHIBITION OF HOST ORGANISMS, IMPROVING BIOMASS PRODUCTIVITY OF HOST ORGANISMS AND/OR PREVAILING OVER OTHER COMPETING ORGANISMS UPON CULTIVATION IN HIGH LIGHT CONDITIONS | Universita' Degli Studi Di Verona | POLIAKOVA-GEORGAN, EKATERINA | 1651 | §103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18639584 | METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | Araris Biotech AG | GUSTILO, ESTELLA M | 1646 | §102Other | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18638034 | CYCLIC UREA KRAS INHIBITORS | Incyte Corporation | KIFLE, BRUCK | 1624 | §112 | Final Rejection | — | Pending | Apr 17, 2024 |
| 18701106 | PROCESSES FOR PREPARING RADIOLABELLED CONJUGATES | University Of Sydney | WESTERBERG, NISSA M | 1618 | §103§112Other | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18699825 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited | KENYON, JOHN S | 1625 | §112DP | Non-Final OA | — | Pending | Apr 09, 2024 |
| 18698440 | SOFTWARE FOR MICROFLUIDIC SYSTEMS INTERFACING WITH MASS SPECTROMETRY | Intabio, LLC | NIMOX, RAYMOND LONDALE | 2857 | §101§103 | Non-Final OA | — | Pending | Apr 04, 2024 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial83.1% of resolved applications prosecuted by Lathrop Gpm LLP were allowed, across 6,812 applications in USPTO records.
3.49 office actions per allowed application on average.
151 pending office actions as of October 2026, for 91 clients, before 137 examiners in 90 art units.
